| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 442 | 393 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 35,422 | 18,660 |
| Cash and cash equivalents at beginning of period | 57,162 | - |
| Cash and cash equivalents at end of period | 92,584 | - |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)